Business Summary: Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Ipsen SA revenues increased 10% to EUR3.93B. Net income applicable to common stockholders excluding extraordinary items increased 25% to EUR443.5M. Revenues reflect Rare Diseases segment increase of 97% to EUR385.1M, Neurosciences segment increase of 7% to EUR746.6M, Europe segment increase of 9% to EUR1.46B, North America segment increase of 11% to EUR1.29B.